Actuate gets $21.7M to expand clinical testing of lead candidate

With its $21.7 million series B round, Actuate plans to expand clinical testing of its GSK3B inhibitor into Europe and advance its pediatric

Read the full 239 word article

How to gain access

Continue reading with a
two-week free trial.